X

Drug Profile

CAN 202

Alternative Names: CAN-202

Latest Information Update: 10 Jan 2023

Price :

$50 ^*

Note:

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Originator CANbridge Pharmaceuticals
Class Gene therapies
Mechanism of Action Gene transference

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

No
New Molecular Entity No

Highest Development Phases

Preclinical Glycogen storage disease type II

Most Recent Events

03 Jan 2023 CANbridge Pharmaceuticals completed adeno-associated virus (AAV) sL65 based capsid technology transfer from LogicBio Therapeutics
16 Nov 2022 LogicBio Therapeutics has been acquired by Alexion AstraZeneca Rare Disease
27 Apr 2021 CANbridge Pharmaceuticals in-licenses adeno-associated virus (AAV) sL65 based capsid technology from LogicBio Therapeutics

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com